Jan Copeland

9.7k total citations · 1 hit paper
178 papers, 7.2k citations indexed

About

Jan Copeland is a scholar working on Pharmacology, Epidemiology and General Health Professions. According to data from OpenAlex, Jan Copeland has authored 178 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pharmacology, 90 papers in Epidemiology and 51 papers in General Health Professions. Recurrent topics in Jan Copeland's work include Cannabis and Cannabinoid Research (89 papers), Substance Abuse Treatment and Outcomes (81 papers) and Homelessness and Social Issues (43 papers). Jan Copeland is often cited by papers focused on Cannabis and Cannabinoid Research (89 papers), Substance Abuse Treatment and Outcomes (81 papers) and Homelessness and Social Issues (43 papers). Jan Copeland collaborates with scholars based in Australia, United States and New Zealand. Jan Copeland's co-authors include Wendy Swift, Peter Gates, Paul Dillon, Greg Martin, Melissa M. Norberg, Wayne Hall, Sally E. Rooke, Louisa Degenhardt, Mark A Bellis and Karen Hughes and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Public Health.

In The Last Decade

Jan Copeland

171 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Young adult sequelae of adolescent cannabis use: an integrative analysis

2014 328 citations Wendy Swift, Jan Copeland et al. profile →

Peers

Countries citing papers authored by Jan Copeland

Since Specialization

Citations

This map shows the geographic impact of Jan Copeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Copeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Copeland more than expected).

Fields of papers citing papers by Jan Copeland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Copeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Copeland. The network helps show where Jan Copeland may publish in the future.

Co-authorship network of co-authors of Jan Copeland

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Copeland. A scholar is included among the top collaborators of Jan Copeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Copeland. Jan Copeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study 2023 ·Psychiatry Research ·Ovidiu Tatar, Amal Abdel‐Baki, Alina Dyachenko, (unknown), Arash Bahremand, Philip G. Tibbo, David Crockford, Marc‐André Roy, Jan Copeland, Benedikt Fischer, Tania Lecomte, José Côté, Clairélaine Ouellet‐Plamondon, (unknown), (unknown), Didier Jutras‐Aswad	2
2	Reducing Cannabis Use in Young Adults With Psychosis Using iCanChange, a Mobile Health App: Protocol for a Pilot Randomized Controlled Trial (ReCAP-iCC) 2022 ·JMIR Research Protocols ·Ovidiu Tatar, Amal Abdel‐Baki, (unknown), Tania Lecomte, Jan Copeland, Pamela Lachance‐Touchette, Stephanie Coronado‐Montoya, José Côté, David Crockford, (unknown), (unknown), Clairélaine Ouellet‐Plamondon, Marc‐André Roy, Philip G. Tibbo, (unknown), Didier Jutras‐Aswad	6
3	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence 2020 ·Drug and Alcohol Review ·Llewellyn Mills, Nicholas Lintzeris, Raimondo Bruno, Mark Montebello, Adrian Dunlop, Rachel Deacon, Jan Copeland, Meryem Jefferies, (unknown), (unknown)	8
4	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial 2020 ·Drug and Alcohol Dependence ·Nicholas Lintzeris, Llewellyn Mills, Adrian Dunlop, Jan Copeland, Iain S. McGregor, Raimondo Bruno, Adrienne Kirby, Mark Montebello, Michelle Hall, Meryem Jefferies, Richard C. Kevin, Anjali Bhardwaj	25
5	Selective attention moderates the relationship between attentional capture by signals of nondrug reward and illicit drug use 2017 ·Drug and Alcohol Dependence ·Lucy Albertella, Jan Copeland, Daniel Pearson, Poppy Watson, Reínout W. Wiers, Mike E. Le Pelley	39
6	Cannabis use and its associated disorders: Clinical care. 2016 ·PubMed ·Jan Copeland	3
7	Rapid elimination of Carboxy-THC in a cohort of chronic cannabis users 2015 ·International Journal of Legal Medicine ·John H. Lewis, Anna Molnár, David Allsop, Jan Copeland, Shanlin Fu	3
8	Opinions and attitudes of cannabis users on cannabis policy and policing 2014 ·Drug and Alcohol Review ·Peter Gates, Jan Copeland, (unknown)	0
9	A postal intervention for dependent cannabis users 2011 ·Drug and Alcohol Review ·Melissa M. Norberg, Tracey Wright, (unknown), Jan Copeland	9
10	The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress 2011 ·Drug and Alcohol Dependence ·David J. Allsop, Melissa M. Norberg, Jan Copeland, Shanlin Fu, Alan J. Budney	153
11	Successful and unsuccessful cannabis quitters: Comparing group characteristics and quitting strategies 2011 ·Substance Abuse Treatment Prevention and Policy ·Sally E. Rooke, Melissa M. Norberg, Jan Copeland	14
12	Alcohol use among culturally diverse communities in Sydney 2009 ·Drug and Alcohol Review ·(unknown), (unknown), Jan Copeland	1
13	Management of cannabis use disorder and related issues. A clinician’s guide. 2009 ·The Oncologist ·Jan Copeland, (unknown), Kathryn Elkins	10
14	Modifiable risk factors of ecstasy use: Risk perception, current dependence, perceived control, and depression 2009 ·Addictive Behaviors ·(unknown), Arbi Ben Abdallah, Jan Copeland, Linda B. Cottler	31
15	Regional differences in injecting practices and other substance use-related behaviour among entrants into opioid maintenance pharmacotherapy treatment in New South Wales, Australia 2006 ·Drug and Alcohol Dependence ·Peter Lawrinson, Jan Copeland, Devon Indig	11
16	The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: Reliability, validity and diagnostic cut-off 2005 ·Drug and Alcohol Dependence ·Greg Martin, Jan Copeland, Peter Gates, Stuart Gilmour	182
17	The Cannabis Problems Questionnaire: Factor structure, reliability, and validity 2005 ·Drug and Alcohol Dependence ·Jan Copeland, Stuart Gilmour, Peter Gates, Wendy Swift	71
18	Patterns and correlates of substance use amongst juvenile detainees in New South Wales 1989–99 2003 ·Drug and Alcohol Review ·Jan Copeland, John Howard, (unknown), (unknown)	17
19	Young offenders, substance use, depression and suicidal behaviour 2001 ·Australian Journal of Psychology ·(unknown), Jan Copeland, J.R. Nicholas, (unknown)	2
20	The measurement of outcome in alcohol and other drug treatment: a review of available instruments. 2000 ·Scientific Repository (Petra Christian University) ·Maree Teesson, (unknown), Jan Copeland, (unknown), Amanda Reid	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact